Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 15-65~2. Patients with ABC (determined by immunohistochemistry using the Hans algorithmI) DLBCL with primary refractory disease, relapse \<12 months after initial therapy, secondary International Prognostic Index (IPI) \>1, less than partial response to salvage treatment or exposure to \>3 salvage regimens~3. Adequate renal function, as defined by an estimated serum creatinine clearance \>/= 50 ml/min (MDRD method) and/or serum creatinine \</= 1.8 mg/dL~4. Adequate hepatic function (SGOT and/or SGPT \</= 3 x ULN; bilirubin and ALP \</= 2 x ULN~5. Adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) \>/= 50%~6. Adequate cardiac function with left ventricular ejection fraction \>/= 40%. No uncontrolled arrhythmias or symptomatic cardiac disease~7. ECOG performance status \<2~8. Negative Beta HCG in woman with child-bearing potential~9. All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program.~10. Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program.~Exclusion Criteria:~1. Grade \>/= 3 non-hematologic toxicity from previous therapy that has not resolved to \</= G1~2. Prior whole brain irradiation~3. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \>/= 10,000 copies/mL, or \>/= 2,000 IU/mL)~4. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology~5. Active infection requiring parenteral antibiotics~6. HIV infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 counts~7. Radiation therapy in the month prior to enrollment~8. History of arterial thromboembolic events in the past 3 months and of venous thromboembolic events in the past month~9. History of hypersensitivity of lenalidomide or thalidomide

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT (Type: EXPERIMENTAL): Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues